

RESEARCH ARTICLE

Open Access

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgG_{Fc} chimeric protein targeting tissue factor

Emiliano Cocco¹, Joyce Varughese¹, Natalia Buza², Stefania Bellone¹, Michelle Glasgow¹, Marta Bellone¹, Paola Todeschini¹, Luisa Carrara¹, Dan-Arin Silasi¹, Masoud Azodi¹, Peter E Schwartz¹, Thomas J Rutherford¹, Sergio Pecorelli³, Charles J Lockwood¹ and Alessandro D Santin^{1*}

Abstract

Background: Cervical cancer continues to be an important worldwide health problem for women. Up to 35% of patients who are diagnosed with and appropriately treated for cervical cancer will recur and treatment results are poor for recurrent disease. Given these sobering statistics, development of novel therapies for cervical cancer remains a high priority. We evaluated the expression of Tissue Factor (TF) in cervical cancer and the potential of hI-con1, an antibody-like-molecule targeted against TF, as a novel form of immunotherapy against multiple primary cervical carcinoma cell lines with squamous- and adenocarcinoma histology.

Methods: Because TF is a transmembrane receptor for coagulation factor VII/VIIIa (fVII), in this study we evaluated the *in vitro* expression of TF in cervical carcinoma cell lines by immunohistochemistry (IHC), real time-PCR (qRT-PCR) and flow cytometry. Sensitivity to hI-con1-dependent cell-mediated-cytotoxicity (IDCC) was evaluated in 5-hrs-⁵¹chromium-release-assays against cervical cancer cell lines *in vitro*.

Results: Cytoplasmic and/or membrane TF expression was observed in 8 out of 8 (100%) of the tumor tissues tested by IHC and in 100% (11 out of 11) of the cervical carcinoma cell lines tested by real-time-PCR and flow cytometry but not in normal cervical keratinocytes ($p = 0.0023$ qRT-PCR; $p = 0.0042$ flow cytometry). All primary cervical cancer cell lines tested overexpressing TF, regardless of their histology, were highly sensitive to IDCC (mean killing \pm SD, $56.2\% \pm 15.9\%$, range, 32.4%-76.9%, $p < 0.001$), while negligible cytotoxicity was seen in the absence of hI-con1 or in the presence of rituximab-control-antibody. Low doses of interleukin-2 further increased the cytotoxic effect induced by hI-con1 ($p = 0.025$) while human serum did not significantly decrease IDCC against cervical cancer cell lines ($p = 0.597$).

Conclusions: TF is highly expressed in squamous and adenocarcinoma of the uterine cervix. hI-con1 induces strong cytotoxicity against primary cervical cancer cell lines overexpressing TF and may represent a novel therapeutic agent for the treatment of cervical cancer refractory to standard treatment modalities.

* Correspondence: alessandro.santin@yale.edu

¹Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, 333 Cedar street, New Haven (06519), CT, USA
Full list of author information is available at the end of the article

Background

Despite aggressive screening programs, cervical cancer remains an important public health issue. In the United States about 12,200 new cases of cervical cancer as well as 4,210 deaths from cervical cancer are estimated for 2010 [1]. Although cervical cancer is, to a large extent, a preventable disease, it remains an important health problem for women, especially in underserved and minority groups in industrially developed nations and women in developing countries without established screening programs. While early stage cervical cancer can be cured by radical surgery or radiotherapy with equal effectiveness [2], pelvic radiation represents the standard therapy for the treatment of locally advanced disease. Despite technological advances, however, up to 35% of patients overall will develop recurrent disease, for which treatment results are poor [3]. A deeper understanding of the molecular basis of cervical cancer has the potential to significantly refine the diagnosis and management of these tumors and may eventually lead to the development of novel, more specific, and more effective treatments for prevention of disease progression following first-line therapy.

Angiogenesis, the formation of new vessels from pre-existing vasculature, is known to represent a critical step in the development, progression and metastatic process of human solid tumors. Tissue factor (TF), a transmembrane receptor for coagulation factor VII/VIIa (fVII), is aberrantly expressed in human cancers and on endothelial cells within the tumor vasculature [4,5]. Importantly, tumor cells characterized by a high production of TF and vascular endothelial growth factor (VEGF), a crucial initiator of angiogenesis, are known to generate solid tumors characterized by intense vascularity and highly aggressive behavior [6]. Consistent with this view, several studies have shown that VEGF is overexpressed and secreted in a variety of human tumors including cervical carcinomas [7] and an elevated expression of VEGF is correlated clinically with cervical cancer metastasis and poor patient survival [8]. While a direct regulation of VEGF expression in human tumor cells by the cytoplasmic tail of TF has been previously demonstrated [7], recent studies indicate that type-2 proteinase activated receptor (PAR-2) is intimately involved in TF-mediated signaling and angiogenesis [9]. These data suggest a potential direct role for TF in tumor growth [9].

hI-con1™ (Iconic Therapeutics, Inc.; Atlanta, GA) is a previously characterized immuno-conjugate molecule developed against TF [10-12]. It is composed of two identical protein chains consisting of human fVII as the targeting domain fused to human IgG₁ F_c as the effector domain; the two chains are held together by the disulfide bonds normally present in IgG. The hI-con1 is

designed to bind to TF with far higher affinity and specificity than can be achieved with an anti-TF antibody. Indeed, the hI-con1 has several important advantages over monoclonal antibodies for targeting TF including: 1) The K_d for fVII domain binding to TF is about 10⁻¹² M [13], in contrast to anti-TF antibodies that have a K_d in the range of 10⁻⁸ to 10⁻⁹ M for TF [14], and 2) the hI-con1 is produced by recombinant DNA technology, allowing a completely human hI-con1 to be made for future clinical trials. Because binding of fVII to TF could induce disseminated intravascular coagulation, a potentially lethal vascular disease, an amino acid substitution was introduced into the fVII domain of the hI-con1 (Lys 341 to Ala) to inhibit initiation of the coagulation pathway without reducing the strong affinity for TF [10,15]. The human F_c domain of the hI-con1 may thus potentially activate powerful cytolytic responses mediated by antibody-dependent cell-mediated cytotoxicity (ADCC) against both TF-expressing tumor cells and tumor vascular endothelial cells that bind the hI-con1 molecule.

To our knowledge, no studies have specifically described the expression of tissue factor in cervical cancer. Therefore, in this report we investigated the expression of TF at mRNA and protein levels in multiple primary cervical tumor cell lines and evaluated for the first time the *in vitro* potential of hI-con1 as a novel immunotherapeutic agent against biologically aggressive cervical cancer cell lines overexpressing TF.

Methods

Establishment of Primary Cervical Cancer Cell Lines

Primary cervical tumor cell lines from eleven patients harboring cervical cancer were obtained from fresh tumor biopsies collected at the time of primary surgery or surgery for cancer recurrence under approval of the Institutional Review Board. Tumors were staged according to the International Federation of Gynecologists and Obstetricians staging system. Source-patient characteristics of these eleven cell lines are described in Table 1. Human papillomavirus (HPV) typing of these specimens was performed by PCR using sequence-specific primers for HPV 16 and 18 against E7 oncoprotein (Integrated DNA Technologies, Coralville, IA), as previously described [16].

Quantitative real-time PCR in Primary Cell Lines

RNA isolation from 11 primary cervical cancer cell lines (Table 1) was performed using TRIzol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Quantitative PCR was done with a 7500 Real Time PCR System using the manufacturer's recommended protocol (Applied Biosystems, Foster City, CA)

Table 1 Patient characteristics from which the 11 primary cancer cell lines were established

Cell line	Age (years)	Race	FIGO Stage	Grade	Histopathology
ADX-1 ARK-1	25	C*	IB	G3	Adenocarcinoma
ADX-2 ARK-2	33	C	IB	G3	Adenosquamous
ADX-3 ARK-3	33	AA**	IB	G3	Adenosquamous
ADX-4 ARK-4	46	C	IB	G2/G3	Adenocarcinoma
CVX-1 ARK-1	35	AA	IB	G3	Squamous
CVX-2 ARK-2	40	C	Recurrence	G3	Squamous
CVX-3 ARK-3	70	C	IB	G3	Squamous
CVX-4 ARK-4	40	C	IB	G3	Squamous
CVX-5 ARK-5	22	C	IB	G3	Squamous
CVX-6 ARK-6	29	C	IB	G3	Squamous
CVX-7 ARK-7	42	C	Recurrence	G3	Squamous

^FIGO, International Federation of Gynecology and Obstetrics

*C, Caucasian;

**AA, African-American

to evaluate expression of TF in all samples. Each reaction was run in duplicate. Briefly, 5 µg of total RNA from each sample was reverse transcribed using SuperScript III first-strand cDNA synthesis (Invitrogen). Five µL of reverse transcribed RNA samples (from 500 µL of total volume) were amplified by using the TaqMan Universal PCR Master Mix (Applied Biosystems) to produce PCR products specific for TF. The primers and probe for TF were obtained from Applied Biosystems (Assay ID Hs01076032_m1). The comparative threshold cycle (C_T) method (Applied Biosystems) was used to determine gene expression in each sample relative to the value observed in the lowest nonmalignant cervical keratinocyte cell sample, using glyceraldehyde-3-phosphate dehydrogenase (Assay ID Hs99999905_m1) RNA as internal control.

TF immunostaining of Formalin-fixed Cervical Cancer Tissues

Formalin-fixed, paraffin-embedded tissue blocks obtained from 5 stage IB patients, 1 stage IIA and 2 stage III B patients (i.e., 4 squamous- and 4 adenocarcinomas) were retrieved from a separate set of 8 patients from the surgical pathology files at Yale University. All tumor samples and eight normal cervical tissue specimens used as controls were reviewed by a surgical

pathologist (NB). The level of TF expression was then evaluated on the most representative block by standard immunohistochemical (IHC) staining. For immunohistochemistry, 4 µm sections were cut from the formalin-fixed paraffin-embedded blocks. Following deparaffinization and rehydration, endogenous peroxidase was blocked in 3% H₂O₂. Steam and high pH (pH 9) were used for antigen retrieval. The slides were then incubated overnight at 4°C with monoclonal anti-TF antibody (No.4509, 1:10 dilution, American Diagnostica, Stamford, CT). EnVision™ system (Dako, Carpinteria, CA) was used for secondary detection and the reactions were visualized with diaminobenzidine. Appropriate positive and negative controls were used with each case. Both cytoplasmic and membranous immunoreactivity was considered positive. Immunostaining was assessed using a semi-quantitative scoring system, as follows: 0, negative (0% to 5% staining); 1+, weakly positive (10% to 20%); 2+, moderately positive (20% to 50%); 3+ and 4+, strongly positive (50% to 75% and over 75%, respectively), as previously described [17].

Flow Cytometry

Clinical grade hI-con1 was produced for Iconic Therapeutics Inc. (Atlanta, GA) by Laureate Pharma, (Princeton, NJ) by cultivation of BHK cells transfected with a vector containing the gene sequence originally described by Hu and Garen [10-12]. The protein was purified by a series of chromatographic steps to a purity adequate for clinical use, formulated in 15 mM HEPES, 150 mM NaCl, 5 mM CaCl₂, 25 mM arginine, 0.01% Tween 80, pH 7.4 buffer and sterile-filtered. It was provided in aliquots of 80 µL at a stock concentration of 350 µg/ml which were used for our flow cytometry and hI-con1-dependent cell-mediated cytotoxicity (IDCC) studies. Briefly, cervical cancer cell lines and phytohemagglutinin (PHA)-stimulated control peripheral blood lymphocytes (PBL) were stained with hI-con1 at a concentration of 30 µg/ml for 30 minutes on ice or with a commercially available FITC-conjugated mouse anti-human TF immunoglobulin (i.e., positive control, BioSource International, Camarillo, CA). After hI-con1 staining, cells were washed twice with the same buffer and secondary mouse-anti-human antibody (IgG₁-FITC, catalog # F0767 Sigma Aldrich, S. Louis, MO) was added for a further 30 minutes. Analysis was conducted with a FACSCalibur instrument using Cell Quest software (Becton Dickinson, Franklin Lakes, NJ).

Tests for IDCC

A standard 5-hours chromium (⁵¹Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-Hypaque-separated PBL from several healthy donors in combination with hI-con1 against cervical cancer cell

lines. The release of ^{51}Cr from the target cells was measured as previously described [17] as evidence of tumor cell lysis after exposure of tumor cells to various concentrations of hI-con1 (ranging from 1 to 80 $\mu\text{g}/\text{ml}$) and different target/effector cells ratios. Controls included the incubation of target cells alone or with PBL or monoclonal antibody (mAb) separately. The chimeric anti-CD20 mAb rituximab (Rituxan[®]; Genentech) was used as control in all bioassays. IDCC was calculated as the percentage of killing of target cells observed with mAb plus effector cells as compared with ^{51}Cr release from target cells incubated alone.

IL-2 Enhancement of IDCC

To investigate the effect of interleukin-2 (IL-2) on IDCC, effector PBL were incubated for 5 hours at 37°C at a final concentration of IL-2 (Aldesleukin; Chiron Therapeutics, Emeryville, CA) ranging from 50 to 100 IU/ml in 96-well microtiter plates. Target cells were primary cervical cancer cell lines exposed to hI-con1 (concentrations ranging from 1 to 80 $\mu\text{g}/\text{ml}$), whereas controls included the incubation of target cells alone or with PBL in the presence or absence of IL-2 or mAb, respectively. Rituximab was used as a control mAb. IDCC was calculated as the percentage of killing of target cells observed with mAb plus effector PBL, as compared with target cells incubated alone. Each experiment was performed with PBL collected from multiple normal donors, with results from a representative donor presented.

Test for complement-mediated target cell lysis and γ -globulin inhibition

A standard five-hour chromium (^{51}Cr) release assay identical to the previous IDCC assays was used, except that human serum in a dilution of 1:2 was added to the effector cells. This human serum was used as a source of complement to test for complement-mediated target cell lysis. To test for the possible inhibition of IDCC against a chemoresistant squamous cervical cancer cell line by physiological human serum concentrations of γ -globulin, human serum was diluted 1:2 before being added in the presence or absence of effector PBL. Experiments were also performed using heat-inactivated human serum (56°C for 60 minutes; diluted 1:2) in the presence of effector PBL. Controls included the incubation of target cells alone or with either PBL or mAb separately. Rituxan was used as a control mAb.

Statistical Analysis

For qRT-PCR data, the right-skewing was removed by taking copy-number ratios relative to the lowest-expressing normal cervical keratinocyte sample ("relative copy numbers"), \log_2 -transforming them to ΔCTs , and

comparing the results via unequal-variance *t*-test for differences between cervical cancer cells versus normal cervical keratinocytes. Group means with 95% confidence intervals (CI) were calculated by computing them on the ΔCTs and then reverse-transforming the results to obtain means (95% CI) of relative copy numbers. Differences in TF expression by IHC and flow cytometry were analyzed by the unpaired *t*-test. Kruskal-Wallis test and chi-square analysis were used to evaluate differences in hI-con1-dependent cell-mediated cytotoxicity levels in primary tumor cell lines. Statistical analysis was performed using SPSS version 17 (SPSS, Chicago, IL). A *p*-value of < 0.05 was considered statistically significant.

Results

Tissue Factor expression by qRT-PCR in primary cell lines

A total of eleven primary cervical cancer cell lines including 7 squamous cervical tumors, 2 cervical adenocarcinomas and 2 adenosquamous tumors were available for this study (Table 1). All primary cervical cancer cell lines were found to harbor HPV 16 or 18 genotypes (data not shown). With the exception of CVX-1 ARK-1 and CVX-7 ARK-7 cervical cancer cell lines, which were derived from biopsies obtained from recurrent carcinoma sites (i.e., a vaginal recurrence, CVX-1 ARK-1) and a metastatic site of disease (CVX-7 ARK-7, i.e., lymph node), all other cell lines were established from biopsies collected at the time of surgery from the primary site of disease (i.e., cervix uteri, Table 1). The mean \pm standard error (minimum-maximum) copy number in tumor samples was 224.8 ± 39.4 (range: 44-613) versus 0.5 (range: 0.02-1) in normal cells (*p* = 0.023). Of the eleven tumors tested, nine showed a high mRNA copy number (i.e., above 100 copies) (Table 2). Squamous tumor cell lines were found to express significantly higher level of TF (mean \pm SE = 297.2 ± 51)

Table 2 Tissue Factor expression by qRT-PCR in primary squamous and adenocarcinoma cervical cancer cell lines

Cell line	qRT-PCR mRNA copy #
ADX-1 ARK-1	46.7
ADX-2 ARK-2	156.5
ADX-3 ARK-3	44.2
ADX-4 ARK-4	289.7
CVX-1 ARK-1	382.1
CVX-2 ARK-2	138.3
CVX-3 ARK-3	137.2
CVX-4 ARK-4	109.6
CVX-5 ARK-5	613.9
CVX-6 ARK-6	123.9
CVX-7 ARK-7	480.6

*qRT-PCR, quantitative Real-time Polymerase Chain Reaction.

of cytotoxicity: 0.5 - 17.6% with all E:T ratios). Similarly, primary cervical cancer cell lines incubated with rituximab (2.5 µg/ml) control antibody displayed no significant cytotoxicity (range: 0.5% - 13.03%). In contrast, as representatively shown in Figure 3, we found all cervical tumor cell lines tested expressing TF, regardless of their squamous or adenocarcinoma histology or their primary versus metastatic/recurrent tumor sites of origin, to be highly sensitive to IDCC (mean ± SD: 56.2% ± 15.9%, range: 32.4% - 76.9% for the E:T ratio 50:1, Figure 3, $p < 0.001$). Importantly, high levels of hI-con1-induced cytotoxicity were also detected against CVX-1 ARK-1, a squamous cervical cancer cell line established from a

patient experiencing recurrent disease after chemotherapy resistant tumor (Figure 3) and CVX-7 ARK-7, a tumor established from a metastatic recurrent site of disease (data not shown). Negligible cytotoxicity was detected against PHA-stimulated PBL controls incubated with hI-con1 (mean ± SD, 4.8% ± 1.8% for the E:T ratio 50:1; Figure 3).

IL-2 Enhancement of IDCC against cervical tumors

To investigate the effect of low doses of IL-2 in combination with hI-con1 (30 µg/ml) on IDCC against primary cervical cancer cell lines, PBL from healthy donors were incubated for 5 hours in the presence of 50 to 100




Figure 3 Representative cytotoxicity experiments using hI-con1 against control PBL and CVX-1 ARK-1, CVX-2 ARK-2 and ADX-1 ARK-1 primary cervical cell lines. Negligible cytotoxicity was detected in the absence of hI-con1 or in the presence of rituximab control mAb.

IU/ml of IL-2. As representatively shown in Figure 4 for CVX-2 ARK-2, in multiple experiments in all cervical tumors tested in the presence of IL-2 (i.e., ADX-1 ARK-1, CVX-1 ARK-1 and CVX-2 ARK-2), IDCC was consistently increased in the presence of low doses of the cytokine. Administration of 50 to 100 IU/ml of IL-2 to the effector PBL at the start of the assay increased the cytotoxic activity against primary cervical cancer cell lines overexpressing TF compared with the use of hI-con1 alone (Figure 4, $p = 0.025$) whereas no significant increase in cytotoxicity was detected after 5 hours of IL-2 treatment in the absence of hI-con1 or in the presence of rituximab control mAb (Figure 4). These results demonstrate that low levels of IL-2 may enhance hI-con1-mediated-cell-cytotoxicity in primary cervical cancer cell lines *in vitro*.

Effect of complement and physiological concentrations of IgG on hI-con1-mediated IDCC



In order to evaluate the effect of complement on the hI-con1-mediated IDCC as well as the potential inhibition of hI-con1 cytotoxic activity by physiological human serum γ -globulin concentrations, human serum diluted 1:2 (with and without heat inactivation) was added to a

representative squamous cervical cancer cell line (CVX-7 ARK-7) during standard 5-hours ^{51}Cr release assays. The addition of untreated or heat inactivated human serum diluted 1:2 did not significantly alter the cytotoxic effect of hI-con1 against CVX-7 ARK-7 cell line when compared to hI-con1-mediated killing without serum ($p = 0.597$, Figure 5).

Discussion

The management of disseminated carcinoma of the cervix that is no longer amenable to control with surgery or radiation therapy has not improved significantly with the advent of modern chemotherapy [2,3]. The one-year survival rate remains between 10 and 15 percent [2,3]. Thus, the development of novel, target-specific and effective modalities against cervical cancer refractory to standard treatments remains desperately needed.

We have evaluated Tissue Factor (TF) expression by qRT-PCR, IHC and flow cytometry in cervical tissue samples and multiple primary cervical cancer cell lines with squamous- and adenocarcinoma histology, some of which were derived from recurrent chemo-radiation resistant tumors. In addition, we have tested the *in vitro* activity of hI-con1, a previously characterized immunoconjugate molecule developed against TF [10-12], as a novel therapy against multiple primary cervical cancer



cell lines *in vitro*. We found both squamous- and adenocarcinoma cell lines to overexpress TF when compared to normal cervical keratinocytes. We speculate that TF expression may be a common and important event in malignant transformation of the cervix into biologically aggressive squamous and adenocarcinoma cervical cancers. Furthermore, both cell lines available to this study established from recurrent/metastatic tumors were found to express extremely high levels of TF. These data are consistent with previous reports in other human solid tumors showing that a high production of TF and vascular endothelial growth factor (VEGF), generate solid tumors characterized by highly aggressive biologic behavior [6]. In this regard, TF is known to be involved in pathological angiogenesis and is abnormally overexpressed in multiple human tumors and in tumor vascular endothelial cells but not on normal quiescent vascular endothelial cells [5,6]. Although TF, as a cell surface receptor, is physiologically expressed on extravascular cells of many organs and in the adventitial layer of the blood vessel wall, it is sequestered by coagulation factor VII (fVII), a natural ligand for TF, at these sites by the tight endothelial cell layer of the normal vasculature [5,6]. Thus, pathologically expressed TF may provide a target for the development of novel cancer therapies effective not only against tumor cells but also tumor blood vessels [10-12,18].

To our knowledge, our results are the first to describe self-production of TF-coagulation factor VII complex by primary cervical cancer cell lines. These data are however consistent with multiple previous reports demonstrating an association between cervical cancer and deep-vein thrombosis and/or pulmonary thromboembolism (i.e., Trousseau syndrome) [19-22], a pathologic state previously reported to be associated with TF overexpression [23]. Importantly, primary cervical cancer cell lines overexpressing TF, regardless of their histology or chemo-radiation therapy resistance, were found to be highly sensitive to hI-con1-mediated cytotoxicity *in vitro*.

TF is known to play an important role in tumor metastatic process, possibly by inducing the coating of the tumor cell with fibrin that would trap the cells in the microvasculature, thereby aiding metastases [24-26]. Recently, however, a possible direct role for TF in tumor growth has also been suggested by studies showing a dramatically reduced tumor growth in mice where a selective reduction in TF was achieved using small interfering RNA [26]. Of great interest, in these studies, the reduction of TF expression did not affect growth of the tumor cells *in vitro*, suggesting that TF-mediated enhancement of tumor growth requires a factor present *in vivo* that is not present when cells are grown *in vitro* [26]. A potential candidate to explain these findings is therefore fVIIa, which would form a TF:fVIIa complex

on the surface of tumor cells *in vivo* leading to activation of type-2 proteinase activated receptor (PAR2) dependent signaling [9]. These findings combined with our results suggest that TF overexpression may potentially provide an additional growth advantage to biologically aggressive cervical cancers *in vivo*.

The potential cytotoxic activity of hI-con1 against human melanoma and prostate tumor cells has previously been demonstrated by Hu et al. [10-12]. In a recent study we extended their results by evaluating the cytotoxic potential of hI-con1 against multiple high grade, biologically aggressive, Type II endometrial cancer cell lines [17]. We found all endometrial carcinomas that showed high TF expression, regardless of their high or low HER2/neu expression, were highly susceptible to IDCC in the presence of effector cells [17]. In the current study we expanded our research work with hI-con1 to multiple primary cervical carcinoma cell lines with squamous and adenocarcinoma histology. It is worth noting that although these cell lines were resistant to natural killer cytotoxic activity, IDCC resulted in killing of up to 50% of tumor cells in 5-hour ⁵¹Cr release assays. Taken together, these *in vitro* results strongly suggest that TF may provide a novel target for the treatment of resistant/residual cervical disease and the destruction of their tumor vasculature that should result in hI-con1-induced lysis of tumor cells as well as tumor endothelial cells *in vivo*. Consistent with this hypothesis and the central role of angiogenesis in cervical cancer development and progression, bevacizumab, a humanized antibody able to bind and inactivate VEGF, has been recently reported to shrink cervical tumors and delay progression without appreciable toxicity. On the basis of these encouraging results, bevacizumab is currently being studied in a Gynecologic Oncology Group (GOG) phase III trial [27].

For effective cytotoxicity, the effector cells must be able to interact with the immune-conjugate at the target site *in vivo*, even in the presence of high concentrations of human IgG. In this study we showed that hI-con1-dependent cytotoxicity against cervical cancer cell lines was not inhibited by high concentrations (up to 50%) of human serum. These data, therefore, suggest that in the presence of effector PBL, human serum may not significantly decrease IDCC against cervical cancer cell lines. Moreover, these results indicate that the binding of hI-con1 to the F_c receptor on mononuclear effector cells is likely to occur *in vivo*.

The degree of ADCC *in vitro* and *in vivo* is known to be mainly dependent on the number and function of NK cells [28]. NK cells are considered to be the best suited lymphocytes for ADCC because they carry F_cγRIII receptors, which are activator molecules, and not F_cγRIIb receptors, which inhibit ADCC [29]. NK cells

also carry receptors for interleukin-2 (IL-2), a cytokine which induces expansion of the NK cell population and enhances their function [29-31]. Therefore, low dose IL-2 administered in the outpatient setting has been previously used to enhance cancer patients' immune response to monoclonal antibodies with little toxicity [30,31]. These findings are particularly interesting because in previous studies we have found that a major barrier to the successful development of therapeutic immunization of advanced cervical cancer patients harboring disease refractory to radiation and chemotherapy was represented by a profound state of immunosuppression present in the majority of these patients [32]. This anergic state, reported by other investigators who have also evaluated the immunocompetence of cervical cancer patients [33], has been attributed to the compounded negative effects of tumor-induced immunomodulation with those resulting from radiation and chemotherapy [34,35]. Importantly, our *in vitro* experiments reveal a significant increase of hI-con1-induced cytotoxicity after the brief incubation of PBL and tumor cells with IL-2 compared to the cytotoxicity induced by hI-con1 in the absence of IL-2. IL-2 seems to therefore enhance the cytotoxic potential of the effector cells. The administration of low doses of IL-2 might therefore be a valid therapeutic option in order to increase IDCC in heavily pretreated cervical carcinoma patients.

Conclusions

In conclusion, high expression of TF in a large number of cervical carcinomas makes hI-con1 an attractive agent for immunotherapy of recurrent/refractory cervical cancer. In this study, we have demonstrated significant hI-con1-mediated killing of multiple primary cervical cancer cell lines regardless of their squamous or adenocarcinoma histology. hI-con1 might therefore represent a novel treatment of this aggressive disease and, potentially, multiple other human tumors overexpressing TF.

Abbreviations

TF: tissue factor; fVI: Factor VI; hI-con1: human immuno-conjugate molecule; IDCC: hI-con1-dependent cell-mediated cytotoxicity; FBS: fetal bovine serum; IHC: immunohistochemistry; mAb: monoclonal antibody; NK cells: natural killer cells; PBL: peripheral blood lymphocytes; qRT-PCR: quantitative real-time-polymerase chain reaction; CVX: cervical squamous cell carcinoma; ADX: cervical adenocarcinoma.

Acknowledgements

The Authors thank Dr. William Konigsberg, Dr. Alan Garen and Dr. Zhiwei Hu for initiating the collaboration with CL on Icon immunotherapy of human gynecologic malignancies and Iconic Therapeutics Inc. for providing hI-con1 protein free of charge for our studies. This work was supported in part by grants from the Angelo Nocivelli, the Berlucchi and the Camillo Golgi Foundation, Brescia, Italy, NIH R01 CA122728-01A2 to AS, and grants 501/A3/3 and 0027557 from the Italian Institute of Health (ISS) to AS. This

investigation was also supported by NIH Research Grant CA-16359 from the National Cancer Institute.

Author details

¹Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, 333 Cedar street, New Haven (06519), CT, USA. ²Department of Pathology, Yale University School of Medicine, 333 Cedar street, New Haven (06519), CT, USA. ³Division of Gynecologic Oncology, University of Brescia, 1 Spedali Civili (52100), Brescia, Italy.

Authors' contributions

EC, JV, SB, MG, MB, PT, and LC carried out the molecular *in vitro* studies including RT-PCR, flow cytometry and IDCC assays, as well as statistical analysis. NB carried out the IHC studies on the tissue samples. DS, MA, PES, TJR, SP, CJL, and AS participated in the design of the study and drafted the manuscript. AS conceived the study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 21 December 2010 Accepted: 22 June 2011

Published: 22 June 2011

References

1. Jemal A, Siegel R, Xu J, Ward E: **Cancer Statistics, 2010.** *CA Cancer J Clin* 2010, **60**:277-300.
2. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C: **Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer.** *Lancet* 1997, **350**:535-40.
3. Disaia PJ, Creasman WT: **Cervical Cancer.** In *Clinical Gynecologic Oncology*. Edited by: Disaia PJ, Creasman WT. St. Louis: Mosby Yearbook, Inc; 1997:1-106.
4. Papetti M, Herman IM: **Mechanisms of normal and tumor-derived angiogenesis.** *Am J Physiol Cell Physiol* 2002, **282**:C947-C970.
5. Contrino J, Hair G, Kreutzer DL, Rickles FR: **In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease.** *Nat Med* 1996, **2**:209-215.
6. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR: **Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.** *Proc Natl Acad Sci USA* 1999, **96**:8663-8668.
7. Santini AD, Hermonat PL, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: **Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix.** *Obstet Gynecol* 1999, **94**:78-82.
8. Goncharuk IV, Vorobjova LI, Lukyanova NY, Chekhun VF: **Vascular endothelial growth factor expression in uterine cervical cancer: correlation with clinicopathologic characteristics and survival.** *Exp Oncol* 2009, **31**:179-81.
9. Ruf W: **Tissue factor and PAR signaling in tumor progression.** *Thromb Res* 2007, **120**:S7-S12.
10. Hu Z, Sun Y, Garen A: **Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model.** *Proc Natl Acad Sci USA* 1999, **96**:8161-8166.
11. Hu Z, Garen A: **Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy.** *Proc Natl Acad Sci USA* 2000, **97**:9221-9225.
12. Hu Z, Garen A: **Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer.** *Proc Natl Acad Sci USA* 2001, **98**:12180-12185.
13. Waxman E, Ross JB, Laue TM, Guha A, Thiruvikraman SV, Lin TC, Konigsberg WH, Nemerson Y: **Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex.** *Biochemistry* 1992, **31**:3998-4003.
14. Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, Schoenfeld J, Lowe D, Lai J, Rancatore P, Iverson M, Lim A, Chisholm V, Kelley RF, Riederer M, Kirchhofer D: **Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic.** *Thromb Haemost* 2001, **85**:379-389.

15. Dickinson CD, Kelly CR, Ruf W: **Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa.** *Proc Natl Acad Sci USA* 1996, **93**:14379-84.
16. Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: **Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.** *J Virol* 2009, **83**:6779-89.
17. Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD: **hI-con1, a factor VII-IgG_{Fc} chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.** *Br J Cancer* 2010, **103**:812-9.
18. Alessi P, Ebbinghaus C, Neri D: **Molecular targeting of angiogenesis.** *Biochim Biophys Acta* 2004, **4**:39-49.
19. Veras E, Srodon M, Neijstrom ES, Ronnett BM: **Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): clinicopathologic characteristics of 2 cases.** *Int J Gynecol Pathol* 2009, **28**:134-9.
20. Simon NL, Orr JW Jr, Hatch KD, et al: **Lower extremity edema due to deep vein thrombosis in patients with recurrent cervix cancer.** *Gynecol Oncol* 1984, **19**:30-3.
21. Mohammed S, Khodadoust K: **Carcinoma of the cervix causing massive intracardiac embolus.** *Gynecol Oncol* 1995, **56**:294-7.
22. Barbera L, Thomas G: **Venous thromboembolism in cervical cancer.** *Lancet Oncol* 2008, **9**:54-60.
23. Satoh T, Oki A, Uno K, Sakurai M, Ochi H, Okada S, Minami R, Matsumoto K, Tanaka YO, Tsunoda H, Homma S, Yoshikawa H: **High incidence of silent venous thromboembolism before treatment in ovarian cancer.** *Br J Cancer* 2007, **97**:1053-7.
24. Rak J, Milsom C, May L, Klement P, Yu J: **Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy.** *Semin Thromb Hemost* 2006, **32**:54-70.
25. Mueller BM, Reisfeld RA, Edgington TS, Ruf W: **Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis.** *Proc Natl Acad Sci USA* 1992, **89**:11832-11836.
26. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW: **Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis.** *Blood* 2005, **105**:1734-1741.
27. Monk BJ, Willmott LJ, Sumner DA: **Anti-angiogenesis agents in metastatic or recurrent cervical cancer.** *Gynecol Oncol* 2010, **116**:181-6.
28. Ortaldo JR, Woodhouse CS, Morgan AC Jr, Herberman RB, Cheresch DA, Reisfeld RA: **Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.** *J Immunol* 1987, **138**:3566-3572.
29. Clynes RA, Towers TL, Presta LG, Ravetch JV: **Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.** *Nature Med* 2000, **6**:443-446.
30. Fehniger TA, Bluman EM, Porter MM, Mrozek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA: **Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.** *J Clin Invest* 2000, **106**:117-124.
31. Caron PC, Lai LT, Scheinberg DA: **Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.** *Clin Cancer Res* 1995, **1**:63-70.
32. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ: **HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.** *Gynecol Oncol* 2006, **100**:469-78.
33. Fiander A, Adams M, Evans AS, Bennett AJ, Borysiewicz LK: **Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients.** *Int J Gynecol Oncol* 1995, **5**:438-42.
34. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S, et al: **Effects of concurrent cisplatin administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix.** *Int J Radiat Oncol Biol Phys* 2000, **48**:997-1006.
35. Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, et al: **Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.** *Int J Radiat Oncol Biol Phys* 2002, **54**:1345-55.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2407/11/263/prepub>

doi:10.1186/1471-2407-11-263

Cite this article as: Cocco et al.: Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgG_{Fc} chimeric protein targeting tissue factor. *BMC Cancer* 2011 **11**:263.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

